Cytori's StemSource(R) Cell Bank to Be Installed for Neo Derm in Hong Kong

SAN DIEGO, CA--(Marketwire - May 4, 2011) - Cytori Therapeutics (NASDAQ: CYTX) will install a comprehensive StemSource® Cell Bank in Hong Kong for Neo Derm (HK) Ltd. Building upon Neo Derm's current use of Cytori's Celution® System, the bank installation will be the first adipose cell and tissue bank in Hong Kong. Neo Derm is Hong Kong's leading provider of medical aesthetic products and services with 18 treatment centers located in Hong Kong and Shanghai, among others, with approximately 900 employees.

"The installation of the StemSource® Cell Bank is an important step to provide our many patients with best in class future aesthetic and rejuvenation treatments," said Mr. Meng Teng Lim, Managing Director of Neo Derm. "We believe that cell-enriched and traditional fat grafting addresses the growing interest among patients in Hong Kong to naturally volumize and rejuvenate their appearance."

With both adipose-derived stem and regenerative cell (ADRC) and tissue banking capabilities, the initial focus of the bank will be on the potential of aesthetic medicine. As part of Neo Derm's network of aesthetic centers, the bank will help fulfill demand for cell-enriched aesthetic procedures. The establishment of this bank with Neo Derm furthers Cytori's belief that the banking model represents the future for aesthetic medicine practices.

"Natural aesthetic medicine represents a major growth opportunity in Hong Kong," said Marc Hedrick, President of Cytori. "We are pleased to be partnering with the leader in the field and look forward to growing this strategic relationship."

The StemSource® Cell Bank includes a StemSource® processing system along with all other equipment, software, database and protocols required to cryopreserve patients' own ADRCs for future use in aesthetic procedures. Cell and tissue banking not only facilitates patient capture for the clinic but also provides economic and process efficiencies that makes these procedures practical for both the doctor and patient.

About Cytori

Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures. www.cytori.com

About Neo Derm (HK) Ltd.

Established in 1997, Neo Derm Group is the fastest-growing professional medical aesthetics provider in Hong Kong, specializing in the distribution and retailing of clinically proven medical aesthetics technologies, equipments, products and treatment services. Neo Derm carries 16 highly regarded brands from around the world, and operates 18 treatment centers in Hong Kong and China. In 2008, the Group won the prestigious Gold Award of the Hong Kong Management Association Quality Award for its corporate and management achievements, being the first in the industry receiving the honor. www.neoderm.com.hk

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.